Skip to content

CONTRIBUTORS

Steven Kornfeld, CFA

Partner, Private Investing

Ryan Biggs, CFA

Co-Head, Private Investing

James Cross, CFA

Co-Head of Private Investing

Robert Stevenson, CFA

Co-Head of Private Investing

Emily McCarthy

Research Associate

Executive Summary

  • The combination of massive demand, persistent inefficiencies and accelerating innovation is creating a compelling opportunity for health care technology investors.
  • Artificial intelligence (AI) is transforming health care by improving productivity, enabling continuous and personalized care, and supporting business models that align incentives around better outcomes.
  • We believe the greatest investment opportunities will emerge from companies that can break the traditional trade-off between cost, access and quality.
  • Franklin Venture Partners focuses on late-stage companies where proven execution translates innovative technologies into scalable business models and durable competitive advantages.
     

Understanding the Health Care Technology Opportunity

Health care has traditionally been viewed as a defensive sector, supported by resilient demand across economic cycles. Today, a convergence of structural and technological forces is expanding the investment narrative. Demographic trends are driving massive demand for care, while longstanding inefficiencies are creating significant opportunities for innovation. Advances in AI are enabling new business models with the potential to improve outcomes, expand access and reduce costs. Collectively, these dynamics are transforming health care from a defensive category into a structural growth market and creating a compelling opportunity for health care technology investors.

Exhibit 1: Health Care Is Moving from a Defensive Category into a Growth Market

Structural Changes in the Health care Industry

Source: Franklin Venture Partners. Views subject to change.

The convergence of structural demand, persistent inefficiencies and advances in technology is creating new opportunities to transform the US health care system. We believe the greatest opportunities will emerge from companies that break the industry’s traditional trade-offs by improving outcomes, expanding access and lowering costs while demonstrating the evidence, adoption and scalability needed to become enduring businesses. By focusing on these characteristics, Franklin Venture Partners seeks to identify and support the technology leaders shaping the future of health care.

WHAT ARE THE RISKS?

All investments involve risks, including possible loss of principal.

Equity securities are subject to price fluctuation and possible loss of principal.

Investment strategies which incorporate the identification of thematic investment opportunities, and their performance, may be negatively impacted if the investment manager does not correctly identify such opportunities or if the theme develops in an unexpected manner. Focusing investments in the health care, information technology (IT) and/or technology-related industries carries much greater risks of adverse developments and price movements in such industries than a strategy that invests in a wider variety of industries.

Investment strategies involving Private Markets (such as Private Credit, Private Equity and Real Estate) are complex and speculative, entail significant risk and should not be considered a complete investment program. Such investments should be viewed as illiquid and may require a long-term commitment with no certainty of return. Depending on the product invested in, such investments and strategies may provide for only limited liquidity and are suitable only for persons who can afford to lose the entire amount of their investment. Private investments present certain challenges and involve incremental risks as opposed to investments in public companies, such as dealing with the lack of available information about these companies as well as their general lack of liquidity. There also can be no assurance that companies will list their securities on a securities exchange, as such, the lack of an established, liquid secondary market for some investments may have an adverse effect on the market value of those investments and on an investor's ability to dispose of them at a favorable time or price.

WF: 12048660

This document is intended to be of general interest only. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund. The information provided for any individual security mentioned is not a sufficient basis upon which to make an investment decision. Investments involves risks. Value of investments may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD (“other foreign currency”). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in derivative instruments, this entails specific risks that may increase the risk profile of the investment product. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any share class with “(Hedged)” in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

Please contact your financial advisor if you are in doubt of any information contained herein.

For UCITS funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

For AIFMD funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the AIFMD Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 32a of the AIFMD Directive.

For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund(s)/ sub-fund(s) and will not be investing directly in the underlying assets of the fund(s)/ sub-fund(s).

This document is issued by Franklin Templeton Investments (Asia) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

Unless stated otherwise, all information is as of the date stated above. Source: Franklin Templeton.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.